Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu, M et al. SEER Cancer Statistics Review, 1975-2016. 2019. https://seer.cancer.gov/csr/1975_2016/. Accessed 15 Oct 2015.
Lin CC, Virgo KS, Robbins AS, Jemal A, Ward EM. Comparison of comorbid medical conditions in the national cancer database and the SEER-medicare database. Ann Surg Oncol. 2016;23:4139–48.
Deng HY, Zheng X, Zha P, Peng L, Huang KL, Qiu XM. Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: a comprehensive systematic review and meta-analysis. Thorac Cancer. 2019;10:571–8.
Zhu L, Cao H, Zhang T, Shen H, Dong W, Wang L, et al. The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltim). 2016;95:e3528.
Bi, G, Yao G, Bian Y, Xue L, Zhang Y, Lu T, et al. The effect of diabetes mellitus on prognosis of patients with non-small-cell lung cancer: a systematic review and meta-analysis. Ann Thorac Cardiovasc Surg. 2019. https://doi.org/10.5761/atcs.ra.19-00170.
Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med. 2010;123:S12–18.
Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16:2965.
Nainggolan L FDA approves Canagliflozin, a first-in-class diabetes drug. 2013. https://www.medscape.com/viewarticle/781709 Accessed 30 Sept 2019.
ClinCalc. The top 200 of 2021. Provided by the ClinCalc Drugstats database. 2021. https://clincalc.com/DrugStats/Top200Drugs.aspx Accessed 11 Jan 2021.
CADTH. Canagliflozin (Invokana) for Type 2 Diabetes Mellitus [Internet]. Ottawa: Canadian Agency for Drugs and Technology in Health; 2015.
Zhang XL, Zhu QQ, Chen YH Li, XL Chen F, Huang JA, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7:e007165.
Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–94.
Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453–67.
Gallwitz B. The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors—real-world data. Eur Endocrinol. 2018;14:17–23.
Cavaiola TS, Pettus J. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes Metab Syndr Obes. 2018;11:133–48.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.
Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142:1712–22.
Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10:eaat5933.
Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5:1048–56.
Li H, Tong CW, Leung Y, Wong MH, To KK, Leung KS. Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase inhibitor-resistant lung cancer. Front Oncol. 2017;7:288.
Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578.
Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60:1862–72.
Molina JR, Yang PG, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.
SEER. Overview of the SEER Program. https://seer.cancer.gov/about/overview.html. Accessed 2 Nov 2021.
CMS. Medicare Program - General Information. http://www.cms.gov/MedicareGenInfo/. Accessed 24 Nov 2021.
SEER-Medicare:: Brief Description of the SEER-Medicare Database. https://healthcaredelivery.cancer.gov/seermedicare/overview/. Accessed 29 Oct 2021.
Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of Surveillance, Epidemiology, and End Results-Medicare Data to Conduct Case-Control Studies of Cancer Among the US Elderly. Am J Epidemiol. 2011;174:860–70.
Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54:e55–64.
Yamamoto L, Yamashita S, Nomiyama T, Kawanami T, Hamaguchi Y, Shigeoka T, et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int. 2021;12:389–98.
Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112:E4111–4119.
Blair SL, Heerdt P, Sachar S, Abolhoda A, Hochwald S, Cheng H, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res. 1997;57:152–5.
Hochwald SN, Harrison LE, Rose DM, Anderson M, Burt ME. gamma-Glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J Natl Cancer Inst. 1996;88:193–7.
Kan O, Baldwin SA, Whetton AD. Apoptosis is regulated by the rate of glucose-transport in an interleukin-3 dependent cell-line. J Exp Med. 1994;180:917–23.
Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA. 1998;95:1511–6.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
Yaribeygi H, Atkin SL, Butler AE, Sahebkar A. Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol. 2019;234:3231–7.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–16.
Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98.
Sugizaki T, Zhu S, Guo G, Matsumoto A, Zhao J, Endo M, et al. Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality. npj Aging Mech Dis. 2017;3:12.
Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48:191–5.
Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev. 2012;2012:542042.
Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92:874–9.